Is there a role for resection of oligometastatic disease in pancreatic ductal adenocarcinoma?  

作　　者：Yana Puckett Mariam F.Eskander Christopher T.Aquina Timothy M.Pawlik 

机构地区：[1]Department of Surgery,West Virginia University School of Medicine,Charleston,WV 25340,USA [2]Department of Surgical Oncology,The Ohio State University,Columbus,OH 43210,USA

出　　处：《Journal of Cancer Metastasis and Treatment》2020年第1期548-555,共8页癌症转移与治疗（英文版）

摘　　要：It is estimated that approximately 80%-90%of pancreatic ductal adenocarcinoma(PDAC)will present with unresectable disease with about half of patients presenting with distant metastases.The prognosis of these patients is generally poor with an average life expectancy of approximately 6 months and a median 5-year survival of 1%.The current standard of care for metastatic PDAC patients is palliative chemotherapy,as surgery in this setting does not lead to better survival.More recently,some centers have utilized very specific patient selection to perform resection of oligometastatic disease with reported improvement in survival-with many centers using response to systemic therapy as a sign of favorable biology.We performed a literature review investigating the role of surgical resection of oligometastatic disease of the lung and liver in PDAC.

关 键 词：Pancreatic cancer pancreatic ductal adenocarcinoma liver metastasis oligometastatic disease M1 SURGERY METASTASECTOMY 

分 类 号：R73[医药卫生—肿瘤]